- Home
- DSM vs ESPR Comparison
DSM vs ESPR Comparison
Compare DSM & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSM
- ESPR
- Stock Information
- Founded
- DSM 1989
- ESPR 2008
- Country
- DSM United States
- ESPR United States
- Employees
- DSM N/A
- ESPR N/A
- Industry
- DSM Investment Managers
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- DSM Finance
- ESPR Health Care
- Exchange
- DSM Nasdaq
- ESPR Nasdaq
- Market Cap
- DSM 289.7M
- ESPR 305.0M
- IPO Year
- DSM N/A
- ESPR 2013
- Fundamental
- Price
- DSM $5.79
- ESPR $1.46
- Analyst Decision
- DSM
- ESPR Buy
- Analyst Count
- DSM 0
- ESPR 7
- Target Price
- DSM N/A
- ESPR $6.36
- AVG Volume (30 Days)
- DSM 161.7K
- ESPR 4.6M
- Earning Date
- DSM 01-01-0001
- ESPR 03-04-2025
- Dividend Yield
- DSM 3.97%
- ESPR N/A
- EPS Growth
- DSM N/A
- ESPR N/A
- EPS
- DSM N/A
- ESPR N/A
- Revenue
- DSM N/A
- ESPR $332,314,000.00
- Revenue This Year
- DSM N/A
- ESPR $5.51
- Revenue Next Year
- DSM N/A
- ESPR $1.42
- P/E Ratio
- DSM N/A
- ESPR N/A
- Revenue Growth
- DSM N/A
- ESPR 185.66
- 52 Week Low
- DSM $4.69
- ESPR $1.47
- 52 Week High
- DSM $6.05
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- DSM 43.56
- ESPR 35.61
- Support Level
- DSM $5.75
- ESPR $1.47
- Resistance Level
- DSM $6.10
- ESPR $1.75
- Average True Range (ATR)
- DSM 0.05
- ESPR 0.10
- MACD
- DSM -0.01
- ESPR 0.00
- Stochastic Oscillator
- DSM 33.33
- ESPR 4.55
About DSM BNY Mellon Strategic Municipal Bond Fund Inc.
BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.